Paraganglioma – Medxy AI

Octreotide in the Management of Catecholamine-Secreting Pheochromocytomas and Paragangliomas: A Promising Adjunctive Therapy

By MedXY 08/22/2026

Octreotide shows potential as an effective adjunctive therapy in catecholamine-secreting pheochromocytomas and paragangliomas, improving biochemical, hemodynamic, and metabolic parameters and supporting perioperative management.

news Oncology Pathology & Lab Medicine/Bệnh học

Safety of Biopsy in Pheochromocytoma and Paraganglioma: What a Global Study Found

By MedXY 05/15/2026

This international study found that biopsy of pheochromocytoma and paraganglioma had low mortality and low serious complication rates, suggesting biopsy may be reasonable in carefully selected patients with expert management.

Diabetes & Endocrinology Oncology

Targeting Tumor Hypoxia Pathways: Belzutifan’s Promise in Advanced Paraganglioma and Pheochromocytoma Treatment

By MedXY 10/25/2025

This article reviews a phase 2 trial of belzutifan, a HIF-2α inhibitor, demonstrating durable antitumor activity and manageable safety in advanced pheochromocytoma and paraganglioma, highlighting its potential as a targeted therapy.